WO2003099212A3 - Mitogen activated protein kinase inhibitor compositions for lymphoma therapy - Google Patents

Mitogen activated protein kinase inhibitor compositions for lymphoma therapy Download PDF

Info

Publication number
WO2003099212A3
WO2003099212A3 PCT/US2003/015911 US0315911W WO03099212A3 WO 2003099212 A3 WO2003099212 A3 WO 2003099212A3 US 0315911 W US0315911 W US 0315911W WO 03099212 A3 WO03099212 A3 WO 03099212A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
activated protein
mitogen activated
kinase inhibitor
lymphoma therapy
Prior art date
Application number
PCT/US2003/015911
Other languages
French (fr)
Other versions
WO2003099212A2 (en
Inventor
Kojo S J Elenitoba-Johnson
Megan S Lim
Original Assignee
Univ Utah Res Found
Kojo S J Elenitoba-Johnson
Megan S Lim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found, Kojo S J Elenitoba-Johnson, Megan S Lim filed Critical Univ Utah Res Found
Priority to AU2003233605A priority Critical patent/AU2003233605A1/en
Publication of WO2003099212A2 publication Critical patent/WO2003099212A2/en
Publication of WO2003099212A3 publication Critical patent/WO2003099212A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition comprising one or more selective inhibitors of a mitogen activated protein kinase (MAPK), which exert potent activity against malignant hematopoietic neoplasms such as lymphoid neoplasms that show over-expression and constituative activation of enzymes in the MAPK family. A composition is also provided comprising at least one selective inhibitor of a mitogen activated protein kinase, and at least one selective inhibitor of a Bcl-2 protein. The compositions can be used for targeted lymphoma therapy by administering the compositions in therapeutic effective amounts to treat malignant lymphoid neoplasms.
PCT/US2003/015911 2002-05-24 2003-05-21 Mitogen activated protein kinase inhibitor compositions for lymphoma therapy WO2003099212A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003233605A AU2003233605A1 (en) 2002-05-24 2003-05-21 Mitogen activated protein kinase inhibitor compositions for lymphoma therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38339802P 2002-05-24 2002-05-24
US60/383,398 2002-05-24

Publications (2)

Publication Number Publication Date
WO2003099212A2 WO2003099212A2 (en) 2003-12-04
WO2003099212A3 true WO2003099212A3 (en) 2004-02-19

Family

ID=29584561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/015911 WO2003099212A2 (en) 2002-05-24 2003-05-21 Mitogen activated protein kinase inhibitor compositions for lymphoma therapy

Country Status (2)

Country Link
AU (1) AU2003233605A1 (en)
WO (1) WO2003099212A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627923A1 (en) * 2004-08-18 2006-02-22 Het Nederlands Kanker Instituut Means and methods for detecting and/or staging a follicular lymphoma cells
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ATE485268T1 (en) 2006-02-16 2010-11-15 Schering Corp PYRROLIDINE DERIVATIVES AS ERK INHIBITORS
MX2010009268A (en) 2008-02-21 2010-09-14 Schering Corp Compounds that are erk inhibitors.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004901A1 (en) * 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004901A1 (en) * 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 61, no. 13, 2001, pages 5106 - 5115 *
DATABASE CAPLUS [online] DAI Y. ET AL.: "Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells", XP002968023, accession no. STN Database accession no. 2001:503995 *
DATABASE CAPLUS [online] HUANG Z. ET AL.: "Small molecule inhibitors of Bcl-2 proteins for inducing apoptosis", XP002968022, accession no. STN Database accession no. 2000:84619 *
DATABASE CAPLUS [online] ISHII Y. ET AL.: "Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells", XP002968021, accession no. STN Database accession no. 2001:573875 *
LEUKEMIA RES., vol. 25, no. 9, 2001, pages 813 - 820 *

Also Published As

Publication number Publication date
WO2003099212A2 (en) 2003-12-04
AU2003233605A8 (en) 2003-12-12
AU2003233605A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
AU747599C (en) Antitumor agents
WO2005110477A3 (en) Combination therapies for cancer and proliferative angiopathies
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
IS2882B (en) Composition of epothilone analogues and active substances for chemotherapy to treat cell proliferative disorders
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
TW200510375A (en) New compounds
HK1074592A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2003002114A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
MXPA05012675A (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors.
WO2003004006A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2002017898A3 (en) Compositions and methods for inducing vasorelaxation
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
WO2006096769A3 (en) Use of alpha-glucosidase inhibitors to treat alphavirus infections
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
WO2004060878A3 (en) Inhibitors of phosphatases
HK1085744A1 (en) Steroid compounds with anti-tumor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP